Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Namodenoson. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 known ✓ | P0DMS8 | 15/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 5/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | PPARG | P37231 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | PPARD | Q03181 | 1/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.82 |
| ▸ | NPC1 | O15118 | 1/20 | 0.82 |
| ▸ | GMNN | O75496 | 1/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.82 |
| ▸ | LMNA | P02545 | 1/20 | 0.82 |
| ▸ | THRB | P10828 | 1/20 | 0.82 |
| ▸ | HPGD | P15428 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Namodenoson SCHEMBL12648571 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AMAPK1MAPT | |
| Namodenoson SCHEMBL15150531 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AMAPK1MAPT | |
| Namodenoson SCHEMBL29523835 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AMAPK1MAPT | |
| Namodenoson SCHEMBL29376760 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AMAPK1MAPT | |
| Namodenoson SCHEMBL14906362 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AMAPK1MAPT | |
| Namodenoson SCHEMBL14518653 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AMAPK1MAPT | |
| Namodenoson SCHEMBL29383836 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AMAPK1MAPT | |
| Namodenoson SCHEMBL15148066 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AMAPK1MAPT | |
| Namodenoson SCHEMBL29762233 | 0.95 | ADORA3 (0.90) | ADORA3ADORA1ADORA2AMAPK1MAPT | |
| SCHEMBL24615079 | 0.91 | ADORA3 (0.84) | ADORA3ADORA1ADORA2AMAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180344655-A1 | FUNCTIONALIZED POLYMERIC PARTICLES FOR TREATMENT OF GLIOMAS | YALE UNIVERSITY | 2018-12-06 | — | — | US | claimed |
| US-20230364057-A1 | BACTERIAL DNA GYRASE INHIBITORS AND METHODS OF USE THEREOF | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230136466-A1 | BACTERIAL DNA GYRASE INHIBITORS AND METHODS OF USE THEREOF | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230002389-A1 | ADENINE ANALOGS, PRODRUGS, DERIVATIVES, COMPOSITIONS AND USES THEREOF | PADIA JANAK KHIMCHAND (US) | 2023-01-05 | — | — | US | disclosed |
| US-20220218712-A1 | TREATMENT OF ALZHEIMER'S DISEASE | SAINT LOUIS UNIVERSITY | 2022-07-14 | — | — | US | disclosed |
| US-20180344655-A1 | FUNCTIONALIZED POLYMERIC PARTICLES FOR TREATMENT OF GLIOMAS | YALE UNIVERSITY | 2018-12-06 | — | — | US | disclosed |
| WO-2012068539-A1 | USE AND COMPOSITION OF QUERCETIN-3'-O-SULFATE FOR THERAPEUTIC TREATMENT | LIMERICK BIOPHARMA, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20110046039-A1 | POST-EXPOSURE PROPHYLAXIS AND TREATMENT OF INFECTIONS | GEORGE MASON INTELLECTUAL PROPERTIES INC. (US) | 2011-02-24 | — | — | US | disclosed |
| WO-2008115707-A2 | POST-EXPOSURE PROPHYLAXIS AND TREATMENT OF INFECTIONS CAUSED BY ANTHRAX | GEORGE MASON INTELLECTUAL PROPERTIES, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218712-A1 | TREATMENT OF ALZHEIMER'S DISEASE | ADORA3, ADORA2A, ADORA1 | ADORA3 1/4885ADORA1 3/4885ADORA2A 2/4885 |
| US-20230002389-A1 | ADENINE ANALOGS, PRODRUGS, DERIVATIVES, COMPOSITIONS AND USES THEREOF | APRT, HPRT1, NUDT1 | ADORA3 16/4885ADORA1 27/4885ADORA2A 13/4885 |
| US-20230364057-A1 | BACTERIAL DNA GYRASE INHIBITORS AND METHODS OF USE THEREOF | TOP1, DNA2, TOP2A | ADORA3 3677/4885ADORA1 3699/4885ADORA2A 3990/4885 |
| US-20180344655-A1 | FUNCTIONALIZED POLYMERIC PARTICLES FOR TREATMENT OF GLIOMAS | PHLPP1, PHLPP2, PLAA | ADORA3 32/4885ADORA1 39/4885ADORA2A 10/4885 |
| US-20230136466-A1 | BACTERIAL DNA GYRASE INHIBITORS AND METHODS OF USE THEREOF | TOP1, DNA2, TOP2A | ADORA3 3677/4885ADORA1 3699/4885ADORA2A 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.